Analysts forecast that TAIWAN LIPOSOME/S (NASDAQ:TLC) will post $590,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for TAIWAN LIPOSOME/S’s earnings, with the highest sales estimate coming in at $670,000.00 and the lowest estimate coming in at $500,000.00. TAIWAN LIPOSOME/S posted sales of $500,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 18%. The company is scheduled to announce its next earnings results on Monday, November 25th.
According to Zacks, analysts expect that TAIWAN LIPOSOME/S will report full-year sales of $6.80 million for the current financial year, with estimates ranging from $6.50 million to $7.12 million. For the next year, analysts expect that the firm will post sales of $2.33 million, with estimates ranging from $2.14 million to $2.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow TAIWAN LIPOSOME/S.
A number of equities analysts have recently issued reports on TLC shares. Robert W. Baird assumed coverage on TAIWAN LIPOSOME/S in a report on Thursday, June 20th. They issued an “outperform” rating for the company. Zacks Investment Research cut TAIWAN LIPOSOME/S from a “buy” rating to a “hold” rating in a report on Saturday, July 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of TAIWAN LIPOSOME/S in a report on Monday, May 20th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. TAIWAN LIPOSOME/S currently has an average rating of “Buy” and an average target price of $9.50.
NASDAQ TLC traded up $0.46 during trading on Monday, reaching $5.48. The company’s stock had a trading volume of 100 shares, compared to its average volume of 634. The company has a market capitalization of $161.22 million and a PE ratio of -11.66. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.69 and a quick ratio of 2.69. The stock has a fifty day moving average of $5.22. TAIWAN LIPOSOME/S has a one year low of $5.00 and a one year high of $11.00.
An institutional investor recently bought a new position in TAIWAN LIPOSOME/S stock. Millennium Management LLC acquired a new stake in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 109,500 shares of the company’s stock, valued at approximately $602,000. Millennium Management LLC owned 0.34% of TAIWAN LIPOSOME/S as of its most recent filing with the Securities & Exchange Commission. 2.94% of the stock is owned by institutional investors.
About TAIWAN LIPOSOME/S
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Further Reading: What does a hold rating mean?
Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.